TG4050

Phase 1 part: Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with TG4050 in Head and Neck Cancer

 

TG4050

The lead Individualized Neoantigen Therapeutic Vaccine (INTV) from our myvac® platform, TG4050 is being further evaluated in a randomized multicenter Phase 2 part of a Phase 1/2 trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (HNSCC).

Discover TG4050

 

Phase 1 part: Proof of Principle in Patients in the Adjuvant Treatment of Head and Neck Cancers

 

Key news
about Phase 1 part

Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings

Download the Article

Download the Rapid Oral Presentation from ASCO 2025
Watch our Chief Medical Officer explain the key data from the trial
Listen to Pr. Ottensmeier explain his views on the data

* requires analytics cookies

In the Phase 1 part (n=32), all patients who received TG4050 remained disease-free for at least two years, providing strong clinical proof of principle.

These positive data presented at ASCO 2025 confirm that TG4050 treatment is safe and feasible in the adjuvant setting of resectable HPV-negative locally advanced head and neck squamous cell carcinoma (HNSCC).

When given as monotherapy in this trial, TG4050 met all trial endpoints and induced long lasting immune responses to vaccine neoantigens that were sustained for up to two years.

Phase 1/2 Critical Milestones

 

Phase 1 − Successfully completed

  • Primary objectives achieved: safety and tolerability
  • Secondary objectives achieved: feasibility, disease-free survival (DFS) => 100% 24-month DFS in treatment arm
  • Additional immunological data from Phase I patients presented at SITC 2025
  • Exploratory objectives: immunogenicity, exploratory tumor biomarkers (TMB, PD-L1) => confirm specific, effective and long-lasting immune response

Phase 2 − Ongoing

  • Primary objective: 2-year median follow-up (2-year DFS)

 

Collaboration agreements

Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050 in the randomized multicenter Phase 1/2 trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers. This Individualized Neoantigen Therapeutic Vaccine is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.

Additional ressources